Blinatumomab for children with B-cell ALL guided by NGS MRD
Treatments studied
Part of Cancer clinical trials.
This trial tests whether a drug called blinatumomab, guided by a sensitive genetic test (NGS MRD), can help treat children with B-cell acute lymphoblastic leukemia (ALL) who are between 1 and 17 years old. The goal is to see if this personalized approach improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) confirmed by standard tests
- Age 1 to 17 years old
- Parent or guardian has agreed to the treatment plan by signing a consent form
- Does not have mature B-cell, mixed-lineage, or T-cell leukemia
- Does not have leukemia that started from another cancer or from CML blast crisis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a drug called blinatumomab can clear leftover leukemia cells in children with B-cell acute lymphoblastic leukemia (B-ALL) who still have traces of disease after standard treatment. It aims to reduce the chance of relapse.
This trial tests a drug called blinatumomab for people with B-ALL whose leukemia has come back at a very low level (detected only by sensitive testing) after a stem cell transplant. The goal is to see if blinatumomab can clear these remaining leukemia cells and prevent a full relapse.
This trial tests blinatumomab, an immune therapy, in young people with B-cell acute lymphoblastic leukemia (B-ALL) after their transplant or when they are getting ready for transplant. The goal is to lower the chance of the leukemia coming back by targeting remaining leukemia cells.
This trial tests a subcutaneous (under the skin) form of blinatumomab for people with B-cell acute lymphoblastic leukemia who are in remission but still have tiny amounts of leukemia cells that can be detected by sensitive tests. The goal is to see if this treatment is safe and can get rid of those remaining cells.
This trial tests a combination of a targeted drug (blinatumomab) with a lower dose of standard chemotherapy for adults newly diagnosed with a certain type of B-cell acute lymphoblastic leukemia. The goal is to see if this approach is effective and causes fewer side effects than full-dose chemotherapy.
This trial tests if a shorter course of blinatumomab can remove minimal residual disease (MRD) — tiny traces of leukemia not seen under a microscope — in people with B-cell acute lymphoblastic leukemia after initial treatment.
Hear when a new Minimal Residual Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.